Rabeprazole Sodium Tablet, Delayed Release
Product Images NDC 68788-7459

5 FDA label images from Preferred Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Rabeprazole Sodium (NDC 68788-7459). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Rabe-str (Rabe Str)

Rabe-str (Rabe Str)
Chemical structure diagram of the active ingredient Rabeprazole Sodium, showing its molecular components including sulfur, nitrogen, oxygen, and sodium atoms arranged in a specific configuration.*
FDA Label Image

Rabe-str2 (Rabe Str2)

Rabe-str2 (Rabe Str2)
A line chart depicts mean heartburn scores over 28 study days comparing placebo, Rabeprazole 10 mg, and Rabeprazole 20 mg groups. The y-axis shows mean score severity from 0 (none) to 4 (very severe). Scores for Rabeprazole groups decrease more than placebo after day 0.*
FDA Label Image

Rabe-str3 (Rabe Str3)

Rabe-str3 (Rabe Str3)
A line graph comparing mean heartburn scores over a 28-day study period between a placebo group (n=58) and a Rabeprazole Sodium 20 mg group (n=59). The x-axis represents study days, ranging from -14 to 28, and the y-axis represents mean heartburn scores from 0 (None) to 4 (Very Severe). Scores decrease notably after day 0 in the Rabeprazole group compared to placebo.*
FDA Label Image

Rabe-str4 (Rabe Str4)

Rabe-str4 (Rabe Str4)
A line graph comparing mean heartburn scores over a 28-day study period between placebo and Rabeprazole Sodium 20 mg groups. The x-axis represents study days from -14 to 28, and the y-axis shows heartburn severity scores from 0 (none) to 4 (very severe). The graph indicates a decrease in heartburn scores for both groups after day 0, with the Rabeprazole group generally showing lower scores than placebo.*
FDA Label Image

Rabeprazole Sodium Delayed-release Tablets 20mg (Rabe 20mg 30tab A)

Rabeprazole Sodium Delayed-release Tablets 20mg (Rabe 20mg 30tab A)
Label for Rabeprazole Sodium Delayed-Release Tablets 20 mg, generic for Aciphex, manufactured by Ascend Laboratories, LLC. The label includes dosage form as yellow round tablets imprinted with "20", storage instructions, and warnings. It features English and Spanish instructions, spaces for lot number, batch, expiration date, and barcode, along with the Preferred Pharmaceuticals, Inc. logo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.